RxDoctor Payments Data

Vincent Ladelia, MD

Cardiovascular Disease · Pine City, NYNPI 1205938263

Payments from drug & device makers

$601in general payments, 2019–2025

Across 25 payments — averaging $24.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$157
  • Johnson & Johnson$87
  • Bardy Diagnostics, Inc.$65
  • Novartis$62
  • E.r. Squibb & Sons, L.L.C.$53
  • Boehringer Ingelheim$49
  • plus $128 from 5 others

What the payments were for

  • Food & beverage$57996%
  • Education$224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$601 in reported general payments places this provider in the 30th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$101,982
Medicare patients
557
Services billed
1,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban300$345,585
EntrestoSacubitril/Valsartan163$143,251
XareltoRivaroxaban62$93,120
BrilintaTicagrelor82$74,000
Repatha SureclickEvolocumab74$56,844
JardianceEmpagliflozin63$43,285
Dofetilide41$20,267
Metoprolol Succinate787$16,232
Praluent PenAlirocumab28$13,383
Ranolazine ErRanolazine65$6,265
Icosapent Ethyl16$5,276
Rosuvastatin Calcium303$4,811
Diltiazem 24hr Er (Cd)Diltiazem Hcl120$4,466
Ezetimibe127$4,196
Isosorbide Mononitrate ErIsosorbide Mononitrate178$3,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$345,585300 claims
NovartisEntresto$62$143,251163 claims
Johnson & JohnsonXarelto$87$93,12062 claims
AstraZenecaBrilinta$11$74,00082 claims
Boehringer IngelheimJardiance$49$43,28563 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Pine City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →